查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1965790

體外肺模型市場－全球產業規模、佔有率、趨勢、機會、預測：按類型、應用、區域和競爭格局分類，2021-2031年

In Vitro Lung Model Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Application, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球體外肺模型市場預計將從 2025 年的 4.6766 億美元大幅成長至 2031 年的 11.5184 億美元，複合年成長率為 16.21%。

這些模型，包括肺晶片平台和類器官，都是實驗室建構的系統，旨在模擬人類呼吸道的生理結構和細胞功能。這些先進的工具使研究人員能夠在可控的體外環境中研究肺部的生物學特性、毒性和藥物反應。市場成長的主要驅動力是監管機構日益成長的壓力，要求以更貼近人體的替代方法取代動物試驗，以及製藥業對預測數據的需求，以最大限度地減少後期臨床試驗的失敗。

市場概覽
預測期 2027-2031
市場規模：2025年 4.6766億美元
市場規模：2031年 11.5184億美元
複合年成長率：2026-2031年 16.21%
成長最快的細分市場 藥物篩檢
最大的市場 北美洲

對這類可靠的臨床前工具的需求進一步受到嚴重呼吸系統疾病日益普遍的推動，使得治療方法的發現變得迫在眉睫。根據美國肺臟協會2024年發布的數據，「預計美國將有約23.5萬人被診斷出患有肺癌」。儘管如此沉重的疾病負擔正在推動相關技術的應用，但阻礙市場擴張的主要挑戰在於複煞車態肺泡-毛細血管界面和血管灌注的生物學複雜性。在實現這些特性方面，高通量篩檢的標準化仍然是一個技術上極具挑戰性且高成本的問題。

市場促進因素

監管和倫理層面向非動物調查方法的轉變正在從根本上重塑全球體外肺模型市場，推動該行業擺脫對體內模型的傳統依賴。這一轉變主要受到鼓勵在新藥申請中使用替代方法數據的法律體制的影響，例如美國FDA現代化法案2.0。隨著監管機構積極檢驗這些平台的有效性，製藥公司正在加速採用人源模型，以提高安全性並減少倫理方面的擔憂。該領域的一項重大進展是FDA正式將這些創新平台納入其官方審查流程。據Emulate公司稱，FDA於2024年9月將首個晶片器官技術納入ISTAND試驗計畫，體現了FDA對這些系統在監管決策中預測能力的核准。

同時，肺晶片系統和3D生物列印技術的突破性進展，正透過解決肺泡界面的生物學複雜性，拓展市場潛力。創新者們正在設計能夠精確模擬人類肺細胞結構、氣體交換和流體動態的支架——這些特徵先前在靜態培養中是無法實現的。例如，Frontier Bio公司在2024年10月宣布，該公司已成功開發出利用幹細胞自組裝成功能性細支氣管的生物列印肺組織，並實現了黏液和界面活性劑的生成。這項技術的成熟正推動著該行業巨大的商業性興趣和投資。根據CN Bio報道，該公司在2024年4月獲得了2,100萬美元的B輪資金籌措，用於擴展其微生理系統，這顯然顯示了業界對非動物模型的日益重視。

市場挑戰

全球體外肺模型市場成長的主要障礙在於，精確複煞車態肺泡-毛細血管界面和血管灌注所涉及的生物複雜性。這項技術難題使得此類模型的開發成本高昂，且難以標準化，以滿足製藥公司所需的高通量篩檢。因此，這些系統通常僅限於小眾學術研究，而無法整合到大規模工業藥物研發流程中，因為它們尚未具備大規模生產所需的穩定性和統一性。無法持續複製人類肺部的生理環境阻礙了市場向商業領域的拓展，而速度、成本效益和可重複性在商業領域至關重要。

缺乏標準化是一個瓶頸，阻礙了製藥業有效解決藥物研發效率日益擴大的問題。製藥公司迫切需要預測工具來加速研發進程，但目前的肺部模型過於複雜，難以快速應用。國際藥品製造商協會聯合會（IFPMA）指出，「從2019年到2023年，臨床試驗從啟動到完成患者招募的平均時間增加了26%。」 雖然這一數據凸顯了臨床工作流程的負擔加重，但體外肺部模型技術要求高、驗證成本高，因此，篩檢檢驗以扭轉這一趨勢的可靠手段，從而阻礙了其市場推廣。

市場趨勢

3D球狀體和類器官培養技術的普及，正將體外肺模型的應用範圍從藥物篩檢擴展到環境毒理學。與靜態2D培養不同，這些自組裝結構能夠模擬評估新型物質呼吸系統效應所需的複雜性。當研究人員檢驗這些系統在奈米毒理學應用中的價值，並確認其在危害識別方面的應用時，這一優勢尤其顯著。曼徹斯特大學於2024年4月發表的一份報告《科學家培養微型人肺作為奈米材料安全測試的動物替代模型》指出，研究人員利用人類肺類器官成功模擬了碳基奈米材料的體內反應，從而建立了一種可靠的非動物安全測試替代方案。這一趨勢預示著類器官的應用前景廣闊，其在工業顆粒物評估中將發揮越來越重要的作用。

同時，患者特異性誘導多能幹細胞（iPS細胞）衍生模型的開發正在革新精準醫療，實現了基於「化身」治療方法的預篩檢。這些工具使臨床醫生能夠在患者自身的組織中測試治療方法，透過確保生物相容性顯著提高臨床試驗的成功率。這項實際應用正在推動國際研究，以更有效地對患者群體進行分層。根據烏得勒支大學醫學中心（UMC Utrecht）於2024年6月發表的題為「囊腫纖維化（CF）患者的獨特臨床試驗：基於類器官的客製化」的報告，患者特異性器官技術正被用於在10個歐洲國家的14個研究中心開展的囊腫纖維化臨床試驗中識別合格的響應者。這種與臨床工作流程的整合表明，個人化模型在降低療法研發風險方面具有日益成長的價值。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球體外肺模型市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 按類型（2D、3D）
    • 依應用領域（藥物篩檢、毒理學、3D模型開發、基礎研究、生理研究、幹細胞研究、再生醫學）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美體外肺模型市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲體外肺模型市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區體外肺模型市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲體外肺部模型市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲體外肺模型市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球體外肺模型市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Epithelix Sarl
  • Mattek Corp.
  • Lonza Group AG
  • Emulate Inc.
  • AlveoliX AG
  • Nortis Inc.
  • CN Bio Innovations Ltd.
  • Mimetas BV
  • InSphero AG
  • ATTC Global

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 24001

The Global In Vitro Lung Model Market is projected to experience substantial growth, rising from USD 467.66 Million in 2025 to USD 1151.84 Million by 2031, reflecting a CAGR of 16.21%. These models, which include lung-on-a-chip platforms and organoids, are laboratory-engineered systems designed to emulate the physiological architecture and cellular functions of the human respiratory tract. Such advanced tools allow researchers to investigate pulmonary biology, toxicity, and drug responses within a controlled setting external to a living organism. The market is chiefly underpinned by increasing regulatory pressure to substitute animal testing with human-relevant alternatives, alongside the pharmaceutical industry's requirement for predictive data to minimize failures in late-stage clinical trials.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 467.66 Million
Market Size 2031USD 1151.84 Million
CAGR 2026-203116.21%
Fastest Growing SegmentDrug Screening
Largest MarketNorth America

The demand for these reliable preclinical tools is further intensified by the rising prevalence of severe respiratory conditions, which necessitates accelerated therapeutic discovery. As stated by the 'American Lung Association', in '2024', 'approximately 235,000 individuals in the United States were projected to receive a lung cancer diagnosis'. Although this significant disease burden fuels adoption, a major challenge hindering market expansion is the biological complexity involved in recreating the dynamic alveolar-capillary interface and vascular perfusion. Achieving these features remains technically difficult and expensive to standardize for high-throughput screening purposes.

Market Driver

The regulatory and ethical transition toward animal-free testing methodologies is fundamentally reshaping the Global In Vitro Lung Model Market, shifting the industry away from its traditional reliance on in vivo models. This change is heavily influenced by legislative frameworks such as the U.S. FDA Modernization Act 2.0, which encourages the use of data from alternative methods for investigational new drug applications. As regulatory bodies actively validate these platforms, pharmaceutical developers are increasingly adopting human-relevant models to enhance safety profiles and mitigate ethical concerns. A pivotal development in this area was the FDA's formal integration of these innovative platforms into its official review process; according to Emulate, Inc., in September 2024, the FDA accepted the first Organ-on-a-Chip technology into its ISTAND Pilot Program, validating the predictive capability of these systems for regulatory decision-making.

Simultaneously, technological breakthroughs in lung-on-chip systems and 3D bioprinting are expanding market capabilities by resolving the biological complexity of the alveolar interface. Innovators are now engineering scaffolds that accurately mimic the cellular architecture, gas exchange, and fluid dynamics of human lungs, features that were previously impossible to replicate in static cultures. For instance, according to Frontier Bio, in October 2024, the company reported the development of bioprinted lung tissue that successfully produces mucus and surfactant, utilizing stem cells to self-organize into functional bronchioles. This technical maturation is driving significant commercial interest and facilitating investment in the sector; according to CN Bio, in April 2024, the company secured $21 million in Series B financing to scale its microphysiological systems, explicitly citing the growing industry adoption of non-animal models.

Market Challenge

The primary obstacle impeding the growth of the Global In Vitro Lung Model Market is the biological complexity associated with accurately recreating the dynamic alveolar-capillary interface and vascular perfusion. This technical intricacy makes the development of these models prohibitively expensive and difficult to standardize for the high-throughput screening required by pharmaceutical companies. Consequently, because these systems are not yet sufficiently robust or uniform for mass production, they are frequently confined to niche academic studies rather than being integrated into large-scale industrial drug discovery pipelines. The inability to consistently replicate the physiological environment of the human lung restricts market expansion into the commercial sector, where speed, cost-efficiency, and reproducibility are paramount.

This lack of standardization creates a bottleneck that prevents the industry from effectively addressing the widening efficiency gap in drug development. Pharmaceutical firms are in urgent need of predictive tools to accelerate timelines, yet current lung models remain too complex to be deployed rapidly. According to the 'International Federation of Pharmaceutical Manufacturers and Associations', in '2024', 'the average time from clinical trial start to patient enrollment close increased by 26% from 2019 to 2023'. This statistic highlights the growing burden on clinical workflows; however, because in vitro lung models remain technically demanding and expensive to validate, they cannot yet be reliably used to screen candidates early enough to reverse this trend, thereby stalling their broader market adoption.

Market Trends

The widespread adoption of 3D spheroid and organoid cultures is expanding the utility of in vitro lung models beyond pharmaceutical screening into the realm of environmental toxicology. Unlike static 2D cultures, these self-organizing structures recapitulate the complexity required to accurately assess the respiratory impact of novel materials. This capability was highlighted when researchers validated these systems for nanotoxicology applications, confirming their value in hazard identification. According to The University of Manchester, April 2024, in the 'Scientists grow human mini-lungs as animal alternative for nanomaterial safety testing' report, researchers successfully utilized human lung organoids to mimic in vivo responses to carbon-based nanomaterials, establishing a robust animal-free alternative for safety testing. This trend signifies a broadening market scope where organoids are becoming increasingly essential for evaluating industrial particulates.

Simultaneously, the development of patient-specific iPSC-derived models is revolutionizing precision medicine by enabling the "avatar-based" pre-screening of therapies. These tools allow clinicians to test treatments on a patient's own tissue, significantly optimizing clinical trial success rates by ensuring biological compatibility. This practical application is driving international research efforts to stratify patient populations more effectively. According to UMC Utrecht, June 2024, in the 'Unique trial patients with CF: customisation with organoids' announcement, a cystic fibrosis clinical trial is utilizing patient-specific organoid technology across 14 centres in 10 European countries to identify eligible responders. This integration into clinical workflows highlights the growing value of personalized models in de-risking therapeutic development.

Key Market Players

  • Epithelix Sarl
  • Mattek Corp.
  • Lonza Group AG
  • Emulate Inc.
  • AlveoliX AG
  • Nortis Inc.
  • CN Bio Innovations Ltd.
  • Mimetas BV
  • InSphero AG
  • ATTC Global

Report Scope

In this report, the Global In Vitro Lung Model Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

In Vitro Lung Model Market, By Type

  • 2D
  • 3D

In Vitro Lung Model Market, By Application

  • Drug Screening
  • Toxicology
  • 3D Model Development
  • Basic Research
  • Physiologic Research
  • Stem Cell Research
  • Regenerative Medicine

In Vitro Lung Model Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global In Vitro Lung Model Market.

Available Customizations:

Global In Vitro Lung Model Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global In Vitro Lung Model Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (2D, 3D)
    • 5.2.2. By Application (Drug Screening, Toxicology, 3D Model Development, Basic Research, Physiologic Research, Stem Cell Research, Regenerative Medicine)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America In Vitro Lung Model Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Application
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States In Vitro Lung Model Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Application
    • 6.3.2. Canada In Vitro Lung Model Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Application
    • 6.3.3. Mexico In Vitro Lung Model Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Application

7. Europe In Vitro Lung Model Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany In Vitro Lung Model Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Application
    • 7.3.2. France In Vitro Lung Model Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Application
    • 7.3.3. United Kingdom In Vitro Lung Model Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Application
    • 7.3.4. Italy In Vitro Lung Model Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Application
    • 7.3.5. Spain In Vitro Lung Model Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Application

8. Asia Pacific In Vitro Lung Model Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China In Vitro Lung Model Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Application
    • 8.3.2. India In Vitro Lung Model Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Application
    • 8.3.3. Japan In Vitro Lung Model Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Application
    • 8.3.4. South Korea In Vitro Lung Model Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Application
    • 8.3.5. Australia In Vitro Lung Model Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Application

9. Middle East & Africa In Vitro Lung Model Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia In Vitro Lung Model Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Application
    • 9.3.2. UAE In Vitro Lung Model Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Application
    • 9.3.3. South Africa In Vitro Lung Model Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Application

10. South America In Vitro Lung Model Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil In Vitro Lung Model Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Application
    • 10.3.2. Colombia In Vitro Lung Model Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Application
    • 10.3.3. Argentina In Vitro Lung Model Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global In Vitro Lung Model Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Epithelix Sarl
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Mattek Corp.
  • 15.3. Lonza Group AG
  • 15.4. Emulate Inc.
  • 15.5. AlveoliX AG
  • 15.6. Nortis Inc.
  • 15.7. CN Bio Innovations Ltd.
  • 15.8. Mimetas BV
  • 15.9. InSphero AG
  • 15.10. ATTC Global

16. Strategic Recommendations

17. About Us & Disclaimer